Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charles River Laboratories Intl. Inc (CRL) vs Opendoor Technologies Inc (OPEN) Price & Performance

Charles River Laboratories Intl. IncTrade
Opendoor Technologies IncTrade

Price performance (Past 24H)

Key statistics

Charles River Laboratories Intl. Inc vs Opendoor Technologies Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $282.01 (market cap $13.22B), while Opendoor Technologies Inc trades at $3.58 (market cap $3.36B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 3.9× Opendoor Technologies Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Opendoor Technologies Inc nearer its low. Which is the better fit depends on your goals.

CRLOPEN
Market Cap
$13.22B$3.36B
Sector
HealthReal Estate
52-Week High
$282.00$10.52
52-Week Low
$145.57$2.42
Enterprise Value
$16.06B$4.43B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $267.49, up 0.75% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.02 versus $2.77 expected, and raised full-year guidance. Despite negative net income margins and high valuation multiples, analyst sentiment remains overwhelmingly positive with 72% buy ratings.

CRL shows operational strength with consistent earnings beats and improved demand, yet faces risks from high debt and profitability challenges. The consensus price target of $277.29 suggests modest upside, but investors must weigh growth prospects against valuation concerns and macroeconomic pressures on biotech spending.

Opendoor Technologies Inc

Opendoor Technologies (OPEN) trades at $3.485, up 1.16% on the day, but remains in a bearish technical trend with weak fundamentals. Revenue has declined from $15.6B in 2022 to $4.37B in 2025, with persistent net losses and a negative net income margin of -46.74%. Recent Q2 2026 earnings missed expectations, and cash flow volatility adds to operational challenges. The stock faces headwinds from a sluggish housing market and high interest rates, as reflected in negative analyst sentiment and a consensus price target of $3.58.

The outlook for OPEN is cautious due to ongoing losses, competitive pressures, and macroeconomic uncertainty. While the low P/S ratio of 0.95 may attract value seekers, significant execution risk and debt levels pose threats. Investor sentiment is predominantly bearish, with 65% of analysts rating Hold. Recovery hinges on sustainable margin improvement and housing market stabilization, but near-term volatility is expected.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL

About Opendoor Technologies Inc

Opendoor Technologies Inc is a digital platform for residential real estate. This platform enables customers to buy and sell houses online. It generates revenue through home sales, along with other revenue from real estate services.

Read more on OPEN